The BMAL1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the BMAL1 (Brain and Muscle ARNT-Like 1) gene has been disrupted. This product provides a genetically heterogeneous pool of CAL-27 cells carrying diverse loss-of-function edits, enabling functional interrogation of BMAL1-dependent transcriptional programs without clonal selection artifacts. Generated via electroporation of Cas9 ribonucleoproteins and validated synthetic guide RNAs, these cells offer a reproducible platform for investigating circadian gene regulation in a human oral carcinoma background.
The parental CAL-27 cell line was originally derived from a human tongue squamous cell carcinoma, a malignancy of the oral cavity. These adherent epithelial cells exhibit hallmarks of the disease, including aberrant proliferation and migration. As a well-characterized oral squamous cell carcinoma (OSCC) model, CAL-27 cells are widely employed to study tumor biology, therapeutic responses, and the molecular mechanisms underlying head and neck cancers. The introduction of a BMAL1 knockout into this background creates a tool to dissect the interplay between circadian clocks and oncogenic processes in OSCC.
BMAL1 encodes a basic helix-loop-helix PAS domain transcription factor that serves as a core component of the mammalian circadian clock. It heterodimerizes with CLOCK or NPAS2 to bind E-box cis-regulatory elements, driving rhythmic expression of period (PER1, PER2) and cryptochrome (CRY1, CRY2) genes, as well as output genes such as DBP. This heterodimer is regulated by upstream factors including ROR?? (activator) and REV-ERB?? (repressor), and its activity is modulated by glucocorticoid signaling. BMAL1 transcriptionally promotes metabolic targets like PPARGC1A, integrating circadian timing with energy homeostasis. The BMAL1:CLOCK complex is also subject to negative feedback by PER:CRY complexes and interaction with cofactor CIPC, which collectively sustain approximately 24-hour oscillations.
In the context of oral squamous cell carcinoma, BMAL1 disruption provides a means to examine how circadian disruption contributes to tumorigenesis, treatment resistance, and metabolic dysregulation. OSCC cells exhibit core clock gene expression, and BMAL1 has been implicated in controlling proliferation, apoptosis, and DNA damage responses. By ablating BMAL1 function, these polyclonal knockout cells permit assessment of altered circadian rhythms on cancer chronobiology, potentially linking circadian misalignment to enhanced tumor aggressiveness or altered drug sensitivity. This model thus bridges circadian biology and oncology within a disease-relevant cellular system.
Researchers can employ these BMAL1 knockout cells in a broad array of experimental workflows. Transcriptomic profiling via RNA-seq and targeted gene expression analysis by RT-qPCR enable characterization of BMAL1-dependent transcriptional networks. Chromatin immunoprecipitation (ChIP-qPCR) allows mapping of E-box occupancy changes. Functional assays such as cell proliferation, migration, and invasion studies reveal phenotypic consequences of BMAL1 loss. Luciferase reporter assays using PER2::LUC or Bmal1-luc constructs provide quantitative circadian rhythm measurements. Additionally, drug sensitivity screens can evaluate the role of the circadian clock in modulating therapeutic responses. For further information, please contact Ascent Research.
